Combination method for treating or preventing childhood atopic disease
The present application describes methods of treating or reducing the onset or occurrence of childhood atopic disease. In particular, it relates to an integrated solution that accounts for temporal and sequential administrations of three different and specific approaches for optimal effectiveness in treating or reducing the onset or occurrence of childhood atopic disease.
1. A method of immune system regulation in an infant, comprising:
identifying an infant at high risk for atopic dermatitis based on at least a parental history of atopic disease;
administering to the infant a composition comprising about 5 billion to about 15 billion colony-forming units (CFU) of Bifidobacterium infantis ( B. infantis ) once daily for at least 12 weeks, wherein the administration starts within about 30 days of birth;
treating the skin of the infant with an effective amount of an emollient, comprising:
about 0.005% to about 0.1% ceramide 3, and
saturated fatty acids,
wherein the ceramide and saturated fatty acids creates a water-impermeable, protective layer to prevent excessive water loss due to evaporation and provide a barrier against the entry of microorganisms,
at least once a day for at least 8 weeks, wherein the treating begins within about 4 days of birth; and
orally administering to the infant a premeasured dose of one to six allergenic foods within about 1-8 months after the birth of the infant;
wherein the method provides a statistically significant reduction in atopic dermatitis at 12 months or at 52 weeks compared to an untreated group in a clinical setting.
2. The method of claim 1 , wherein the composition comprises about 8 billion CFU of B. infantis.
3. The method of claim 1 , wherein the B. infantis composition is administered as a mixture with breast milk.
4. The method of claim 1 , wherein the B. infantis composition is administered as a mixture with infant formula.
5. The method of claim 1 , wherein the allergenic foods are include at least one of cow milk, egg, peanut, wheat, soy, sesame, fish, shellfish, or and tree nut.
6. The method of claim 1 , wherein the method provides a 50% reduction of atopic dermatitis at 6 months.
7. The method of claim 1 , wherein the method provides a 29% reduction of atopic dermatitis at 12 months.
8. The method of claim 1 , wherein the emollient comprises:
a. less than about 1.0% caprylic/capric triglyceridem
b. less than about 0.1% citric acid,
c. less than about 2.0%; benzoic acid,
d. less than about 2.0% potassium phosphate,
e. less than about 10.0% dimethicone,
f. less than about 2.0% palmitic acid,
g. less than about 10% isocetyl alcohol,
h. less than about 2.0% Avena sativa (oat) kernel flour,
i. less than about 2.0% ethylhexylglycerin,
j. less than about 1.0% Avena sativa (oat) kernel oil,
k. less than about 1.0% Avena sativa (oat) kernel extract,
l. Less than about 40% water,
m. less than about 50% glycerin,
n. less than about 2.0% sodium cetearyl sulfate,
o. less than about 2.0% dipotassium phosphate,
p. less than about 1.0% sodium hydroxide,
q. less than about 10.0% cetyl alcohol,
r. less than about 10.0% cetearyl alcohol,
S. less than about 2.0% benzyl alcohol, and
t. less than about 2.0% p-anisic acid.
9. The method of claim 8 , wherein the emollient comprises:
a. at least about 0.005% caprylic/capric triglyceride;
b. at least about 0.005 citric acid;
c. at least about 0.1% benzoic acid,
d. at least about 0.05% potassium phosphate,
e. at least about 1.0% dimethicone,
f. at least about 0.1% palmitic acid,
g. at least about 1.0% isocetyl alcohol,
h. at least about 0.1% Avena sativa (oat) kernel flour,
i. at least about 0.1% ethylhexylglycerin,
j. at least about 0.005% Avena sativa (oat) kernel oil,
k. at least about 0.005% Avena sativa (oat) kernel extract,
l. At least about 15.0% water,
m. at least about 20.0% glycerin,
n. at least about 0.1% sodium cetearyl sulfate,
o. at least about 0.1% dipotassium phosphate,
p. at least about 0.005% sodium hydroxide,
q. at least about 1.0% cetyl alcohol,
r. at least about 1.0% cetearyl alcohol,
s. at least about 0.1% benzyl alcohol, and
t. at least about 0.1% p-anisic acid.
10. The method of claim 9 , wherein, in the emollient,
i. caprylic/capric triglyceride creates a barrier on the skin's surface, which helps to reduce skin dryness by decreasing the loss of moisture;
ii. dimethicone acts as a skin protectant;
iii. stearic acid and palmitic acid create an occlusive barrier that protects skin from unwanted microbes and pollutants while retaining moisture; and
iv. glycerin hydrates the outer layer of the skin and improves skin barrier function and skin mechanical properties.
11. The method of claim 1 , wherein the B. infantis is strain EVC001.
12. The method of claim 1 , further comprising co-administering with the B. infantis one or more probiotics different from B. infantis.
13. The method of claim 12 , wherein the one or more probiotics is selected from Lactiplantibacillus plantarum, Limosilactobacillus fermentum , and Ligilactobacillus salivarius.
14. The method of claim 1 , further comprising monitoring stool samples of the infant to determine colonization of B. infantis.
15. The method of claim 1 , wherein the premeasured dose is between about 0.01 and 0.3 grams.
16. The method of claim 1 , further comprising administering a maintenance dose of each allergenic food.
17. The method of claim 16 , wherein the maintenance dose of each food allergen is between about 0.05 and 1 grams.
18. The method of claim 1 , wherein the treating of the skin of the infant is before the administering to the infant the B. infantis.
19. The method of claim 1 , wherein the treating of the skin of the infant is after the administering to the infant the B. infantis.
20. The method of claim 1 , wherein the emollient comprises colloidal oatmeal and distearyldimonium chloride.